101 related articles for article (PubMed ID: 29978302)
1. [Prediction of unplanned discontinuation of treatment in patients with castration-resistant prostate cancer-results from the IBuTu study].
Honecker F; Wedding U; Kallischnigg G; Schroeder A; Klier J; Frangenheim T; Weißbach L
Urologe A; 2018 Aug; 57(8):909-918. PubMed ID: 29978302
[No Abstract] [Full Text] [Related]
2. Risk factors for unplanned discontinuation of scheduled treatment in elderly patients with castration-resistant prostate cancer: results of the IBuTu study.
Honecker F; Wedding U; Kallischnigg G; Schroeder A; Klier J; Frangenheim T; Weißbach L
J Cancer Res Clin Oncol; 2018 Mar; 144(3):571-577. PubMed ID: 29299751
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer: CYP17A1 inhibitor failure-lessons for future drug development.
Sharifi N
Nat Rev Urol; 2015 May; 12(5):245-6. PubMed ID: 25823374
[No Abstract] [Full Text] [Related]
4. Efficacy and safety of docetaxel and prednisolone for castration-resistant prostate cancer: a multi-institutional retrospective study in Japan.
Fukuta F; Kitamura H; Yanase M; Taguchi K; Takahashi A; Kunishima Y; Miyake M; Adachi H; Itoh N; Hirose T; Takagi S; Miyao N; Matsukawa M; Shigyo M; Masumori N
Jpn J Clin Oncol; 2015 Jul; 45(7):682-7. PubMed ID: 25862824
[TBL] [Abstract][Full Text] [Related]
5. Reply to K. Lu.
Fizazi K; Dreicer R
J Clin Oncol; 2015 Oct; 33(28):3222. PubMed ID: 26215954
[No Abstract] [Full Text] [Related]
6. Reply to K. Lu.
Morris MJ
J Clin Oncol; 2015 Oct; 33(28):3222-3. PubMed ID: 26215948
[No Abstract] [Full Text] [Related]
7. A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.
Ueda Y; Matsubara N; Takizawa I; Nishiyama T; Tabata K; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H
Jpn J Clin Oncol; 2015 Aug; 45(8):774-9. PubMed ID: 25981621
[TBL] [Abstract][Full Text] [Related]
8. The Negative Is Not So Negative: What Do We Learn From Trials With Orteronel?
Lu K
J Clin Oncol; 2015 Oct; 33(28):3221. PubMed ID: 26215959
[No Abstract] [Full Text] [Related]
9. Prolonged biochemical response after discontinuation of orteronel (TAK-700) in a patient with metastasized castration-resistant prostate cancer.
Manenschijn L; Hamberg P
Acta Oncol; 2016 May; 55(5):656-8. PubMed ID: 27046420
[No Abstract] [Full Text] [Related]
10. Re: Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) plus Prednisone with Placebo plus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer that has Progressed during or after Docetaxel-Based Therapy: ELM-PC 5.
Taneja SS
J Urol; 2015 Oct; 194(4):990. PubMed ID: 26382777
[No Abstract] [Full Text] [Related]
11. Failure of ELM-PC 5: an ineffective drug or an unfit end point?
Morris MJ
J Clin Oncol; 2015 Mar; 33(7):679-81. PubMed ID: 25646190
[No Abstract] [Full Text] [Related]
12. The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score.
Miller K; Carles J; Gschwend JE; Van Poppel H; Diels J; Brookman-May SD
Eur Urol; 2018 Jul; 74(1):17-23. PubMed ID: 28939004
[TBL] [Abstract][Full Text] [Related]
13. What is the appropriate use of palliative docetaxel in castration-resistant prostate cancer?
Steineck G; Glimelius B
Acta Oncol; 2013 Nov; 52(8):1589-92. PubMed ID: 24102178
[No Abstract] [Full Text] [Related]
14. The "artificial" docetaxel space: the evolving treatment paradigm of metastatic castration-resistant prostate cancer.
Orsola A; Bellmunt J
Eur Urol; 2015 Jan; 67(1):30-32. PubMed ID: 25108578
[No Abstract] [Full Text] [Related]
15. Clarification to provide further understanding of the conduct and design of TROPIC: A Phase 3 trial of cabazitaxel versus mitoxantrone in patients with metastatic castration-resistant prostate cancer.
De Bono J; Shen L; Sartor O
Arch Ital Urol Androl; 2016 Mar; 88(1):72-3. PubMed ID: 27072184
[No Abstract] [Full Text] [Related]
16. Reply to: Clarification to provide further understanding of the conduct and design of TROPIC: A Phase 3 trial of cabazitaxel versus mitoxantrone in patients with metastatic castration-resistant prostate cancer.
Perletti G
Arch Ital Urol Androl; 2016 Mar; 88(1):74-5. PubMed ID: 27072185
[No Abstract] [Full Text] [Related]
17. The oncological outcomes and risk stratification in docetaxel chemotherapy for castration-resistant prostate cancer.
Shiota M; Yokomizo A; Adachi T; Koga H; Yamaguchi A; Imada K; Takeuchi A; Kiyoshima K; Inokuchi J; Tatsugami K; Naito S
Jpn J Clin Oncol; 2014 Sep; 44(9):860-7. PubMed ID: 24951829
[TBL] [Abstract][Full Text] [Related]
18. [Dexamethasone therapy for castration-resistant prostate cancer].
Nishimura K
Nihon Rinsho; 2016 May; 74 Suppl 3():601-4. PubMed ID: 27344801
[No Abstract] [Full Text] [Related]
19. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
de Bono JS; Smith MR; Saad F; Rathkopf DE; Mulders PFA; Small EJ; Shore ND; Fizazi K; De Porre P; Kheoh T; Li J; Todd MB; Ryan CJ; Flaig TW
Eur Urol; 2017 Apr; 71(4):656-664. PubMed ID: 27402060
[TBL] [Abstract][Full Text] [Related]
20. Abiraterone acetate + prednisolone treatment beyond prostate specific antigen and radiographic progression in metastatic castration-resistant prostate cancer patients.
Biró K; Budai B; Szőnyi M; Küronya Z; Gyergyay F; Nagyiványi K; Géczi L
Urol Oncol; 2018 Feb; 36(2):81.e1-81.e7. PubMed ID: 29153623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
